MedTrace Logo

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

NCT00786682 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-08-14

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hydroxychloroquine may help docetaxel work better and kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving docetaxel together with hydroxychloroquine works in treating patients with metastatic prostate cancer.

Conditions

Interventions

DRUG

docetaxel

DRUG

hydroxychloroquine

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Medicine and Dentistry of New Jersey

    lead OTHER

Principal Investigators

  • Mark Stein, MD · Rutgers Cancer Institute of New Jersey

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00786682 on ClinicalTrials.gov